Regeneron Pharmaceuticals Inc (OQ:REGN)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 777 Old Saw Mill River Road
TARRYTOWN NY 10591
Tel: N/A
Website: https://www.regeneron.com
IR: See website
<
Key People
Leonard S. Schleifer
Co-Chairman of the Board, President, Chief Executive Officer, Founder
George D. Yancopoulos
Co-Chairman of the Board, President, Chief Scientific Officer
Christopher R. Fenimore
Chief Financial Officer, Senior Vice President - Finance
Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Marion E. McCourt
Executive Vice President - Commercial
Andrew J. Murphy
Executive Vice President - Research
Neil Stahl
Executive Vice President - Research and Development
Jason Pitofsky
Vice President, Controller
Business Overview
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; REGEN-COV; Kevzara (sarilumab) Injection, and others.
Financial Overview
For the fiscal year ended 31 December 2023, Regeneron Pharmaceuticals Inc revenues increased 8% to $13.12B. Net income decreased 9% to $3.95B. Revenues reflect Sanofi segment increase of 33% to $3.8B, Libtay-ROW segment increase from $73M to $324.3M. Net income was offset by Selling, general increase of 25% to $2.32B (expense), Research and development increase of 21% to $2.41B (expense).
Employees: 13,450 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $97,921M as of Dec 31, 2023
Annual revenue (TTM): $13,117M as of Dec 31, 2023
EBITDA (TTM): $4,654M as of Dec 31, 2023
Net annual income (TTM): $3,954M as of Dec 31, 2023
Free cash flow (TTM): $3,668M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 109,761,896 as of Jan 25, 2024
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.